Identify patient-reported outcomes and tools that can be incorporated into the clinical setting to measure response to MS treatment

This activity provides a case example of a patient with Duchenne Muscular Dystrophy (DMD), explains the genetic causes of DMD, and discusses the preliminary outcomes of 3 clinical trials using gene therapy to treat DMD.

Apply evidence on novel therapies to the treatment of patients with NMOSD.

 Implement strategies to select optimal evidence-based treatments for patients in the early stages of MS

Review safety data from clinical trials with fenfluramine for the management of children with DS and their impact on patient monitoring and communications to patients and caregivers

Discuss sequencing considerations, including vaccines, that can impact the choice for the most appropriate MS therapy

This activity features the perspectives of multiple sclerosis specialists on the rationale and clinical utility of recently approved and emerging disease-modifying therapies.